We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
189 result(s) found, displaying 71 to 80
-
Prescription medicine registrationActive ingredients: mirikizumab.
-
Prescription medicine decision summaryWe have approved Retevmo (selpercatinib) to treat adult patients with Non-Small Cell Lung Cancer (NSCLC).
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: selpercatinib.
-
Prescription medicine registrationActive ingredients: baricitinib.
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: tirzepatide.
-
Australian public assessment report (AusPar)New AusPAR for Verzenio (Abemaciclib) for the treatment of patients with HR+, HER2-, node-positive early breast cancer.